Navigation Links
US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
Date:6/2/2008

f Azacitidine for castration-resistant prostate cancer

progressing on combined androgen blockade

-- Phillip Periman, M.D., Texas Oncology-Amarillo: Phase II study of

Sunitinib malate for metastatic castration-resistant prostate cancer

following docetaxel-based chemotherapy

-- Allen Cohn, M.D., Rocky Mountain Cancer Centers-Midtown, co-chair,

US Oncology GI Cancer Research Committee: Phase III Panitumumab (pmab)

regimen evaluation in colorectal cancer to estimate primary response

to treatment (PRECEPT): effect of KRAS mutation status on second-line

treatment (tx) with pmab and FOLFIRI

-- Thomas Hutson, D.O., PharmD, Texas Oncology-Baylor Charles A Sammons

Cancer Center, associate chair, US Oncology GU Cancer Research

Committee,: RAD001 plus best supportive care (BSC) vs BSC plus

placebo in patients with metastatic renal cell carcinoma (RCC), which

has progressed on VEGF-TKI therapy: results from a randomized,

double-blind, multicenter Phase III study; Phase III randomized study

of overall survival with sunitinib versus interferon (IFN)-alfa as

first-line treatment of metastatic renal cell carcinoma (mRCC);

Multicenter, Phase I/II study of sunitinib in combination with

docetaxel and prednisone in patients with metastatic

castrate-resistant prostate cancer (mCRPC)-preliminary results;

Biomarker analysis and final results of a phase II renal cell

carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis

inhibitor; A multicenter, prospective Phase II trial of sorafenib in

patients (Pts) with metastatic clear cell renal cell carcinoma

(mccRCC) refractory to prior sunitinib or bevacizumab

-- Kelly Pendergrass, M.D., Kansas City Cancer Center-South:

Characterization of hyperglycemia, hypercholesterolemia, an
'/>"/>

SOURCE US Oncology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
3. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
4. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
7. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
9. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
10. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
11. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email: